AIDS Malignancy Consortium (AMC) Domestic Scholar Award – Applications due July 16, 2021
To download a copy of the application form, click here.
To download a copy of the application form, click here.
The U.S. National Cancer Institute (NCI)-funded AIDS and Cancer Specimen Resource (ACSR) is pleased to announce the release of the Young Investigator Pilot Award (YIPA) for 2021. We welcome applications …
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- …
Everyday, but most especially today, World Cancer Day, the ACSR stands up to cancer. Together, all of our actions matter and the ACSR recommits to supporting our cancer warriors in …
Congratulations to the ACSR’s Dr. Alanna Maguire whose work was featured in a NanoString Technologies, Inc. webinar showcasing how Rosalind® was used to identify novel markers and potential therapeutic targets …
Using ACSR Specimens, Colm Keane et al. give us the largest in-depth description of the biology of Primary Central Nervous Lymphoma occurring in patients with AIDS. This disease demonstrates a …
The AACR Annual Meeting 2021 will be presented over two separate weeks: April 10-15, 2021May 17-21, 2021 Registration includes access to both weeks and on-demand access to all sessions through …
Congratulations to ACSR Technology Core Principal Investigator, Dr. Lisa Rimsza, one of three newly elected Lymphoma Research Foundation Scientific Advisory Board Members! Meet the LRF Scientific Advisory Board Members here: …
amfAR’s “Meet the Scientists” discussion, featured some fascinating research by ACSR collaborator, Dr. Tim Schacker! Watch the playback below if you missed it! Click here to watch: amfAR’s Meet the Scientists …
Notice Number NOT-CA-20-098 Notice of Intent to Publish a Funding Opportunity Announcement for Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional) The National Cancer Institute …